Kaitlyn D’Onofrio

DocwireNews

Patients undergoing maintenance dialysis for chronic kidney disease who do not have hyperparathyroidism will not reduce their risk of certain cardiovascular events with oral&nbsp;alfacalcidol, according to a new study.&nbsp;The study&nbsp;randomized&nbsp;976 patients from&nbsp;108&nbsp;dialysis centers in Japan&nbsp;receiving maintenance hemodialysis with serum intact parathyroid hormone levels less than or equal to 180&nbsp;pg/mL&nbsp;between Aug. 18, 2008, and Jan. 26, 2011. Final follow-up was on April 4, 2015. Patients were treated either&nbsp;with 0.5&nbsp;&mu;g&nbsp;of oral&nbsp;alfacalcidol&nbsp;per day (intervention group; n = 495)&nbsp;or&nbsp;without vitamin D receptor activators (control group; n = 481).&nbsp;Primary outcomes were fatal and nonfatal cardiovascular (CV) events,&nbsp;myocardial infarctions, hospitalizations for congestive heart failure, stroke, aortic dissection/rupture, amputation of lower limb due to ischemia, and cardiac sudden death; coronary revascularization; and leg artery revascularization. Secondary outcome was all-cause mortality.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Oral alfacalcidol, a vitamin D receptor activator (VDRA), is not associated with reduced cardiovascular risk among patients without secondary hyperparathyroidism receiving maintenance hemodialysis. <a href="https://twitter.com/JAMA_current?ref_src=twsrc%5Etfw">@JAMA_current</a>
&mdash; PhysiciansFirstWatch (@Physns1stWatch) <a href="https://twitter.com/Physns1stWatch/status/1073042079226490881?ref_src=twsrc%5Etfw">December 13, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Of the total cohort, 944 patients completed the trial (intervention group, 488; control group, 476). CV events occurred in 21.1% (n = 103/488) of the intervention group and 17.9% (n = 85/476) of the control group&nbsp;(absolute difference, 3.25% [95% CI, &minus;1.75% to 8.24%]; hazard ratio, 1.25 [95% CI, 0.94-1.67]; P = .13).&nbsp;All-cause mortality rates were 18.2% in the intervention group and 16.8% in the control group (hazard ratio, 1.12 [95% CI, 0.83-1.52]; P = .46).&nbsp;Serious CV-related adverse events occurred in 40.8% (n = 199) of the intervention group; 13.1% (n = 64) sustained an infection, and 4.5% (n = 22)&nbsp;experienced malignancy-related serious adverse events. In the control group. 40.1% (n = 191) had a serious CV-related adverse event, while 13.2% (n = 63) and 4.4% (n = 21) experienced serious infection and&nbsp;malignancy-related adverse events, respectively.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Alfacalcidol Does Not Lower CV Risk in Dialysis, Trial Suggests <a href="https://t.co/lp9cn4lrlu">https://t.co/lp9cn4lrlu</a> via <a href="https://twitter.com/Medscape?ref_src=twsrc%5Etfw">@medscape</a>
&mdash; Irish Medicines Formulary (IMF) and IMF-Online (@FormularyIE) <a href="https://twitter.com/FormularyIE/status/1074691946440986624?ref_src=twsrc%5Etfw">December 17, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without SecHPT Receiving Maintrnance Hemodialysis: The J-DAVID Randomized Clinical Trial. J-DAVID Investigators, Shoji T et al. JAMA. 2018 Dec 11 <a href="https://t.co/A0Q4ypgE2B">https://t.co/A0Q4ypgE2B</a> &hellip;no significant effect <a href="https://t.co/6ZkaIfzwBU">pic.twitter.com/6ZkaIfzwBU</a>
&mdash; Osteoporosis NL (@Osteoporosis_NL) <a href="https://twitter.com/Osteoporosis_NL/status/1073139298923413504?ref_src=twsrc%5Etfw">December 13, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>The study&rsquo;s findings appear in&nbsp;JAMA.&nbsp;The researchers wrote, in sum, &ldquo;Among patients without secondary hyperparathyroidism undergoing maintenance hemodialysis, oral&nbsp;alfacalcidol&nbsp;compared with usual care did not reduce the risk of a composite measure of select cardiovascular events. These findings do not support the use of vitamin D receptor activators for patients such as these.&rdquo;&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Open-label RCT of alfacalcidol vs. control shows no effect on CVD in ESKD. Some reservations re. trial design and inclusion criteria aside, I can&rsquo;t say I&rsquo;m surprised. Worry that much (if not) all we do to treat MBD in clinical practise is useless for CVD&hellip; <a href="https://t.co/wb8KAQ8zuo">https://t.co/wb8KAQ8zuo</a>
&mdash; Iain Bressendorff, MD PhD (@IBressendorff) <a href="https://twitter.com/IBressendorff/status/1072790001128226817?ref_src=twsrc%5Etfw">December 12, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><a href="https://proddocwire.wpengine.com/conference-coverage/american-heart-association-2018-scientific-sessions/vital-omega-3-and-vitamin-d-supplements-did-not-reduce-major-cvd-events-invasive-cancers/">VITAL: Omega-3 and Vitamin D Supplements Did Not Reduce Major CVD Events, Invasive Cancers</a>&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/study-vitamin-d-supplements/">Study: Vitamin D Supplements Do Not Affect Bone Health</a>&nbsp;<a href="https://proddocwire.wpengine.com/abstracts/vitamin-d3-administration-inflammatory/">The effect of vitamin D administration on inflammatory markers in patients with inflammatory bowel disease</a>&nbsp;<a href="https://proddocwire.wpengine.com/abstracts/prevalence-vitamin-d-deficiency/">Prevalence of vitamin D deficiency in postmenopausal high- and low-energy fracture patient</a>&nbsp;Source:&nbsp;<a href="https://jamanetwork.com/journals/jama/article-abstract/2718066">JAMA</a>

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Active Vitamin D Does Not Reduce CV-related Risk for Certain Dialysis Patients

Chronic Kidney Disease

Patients undergoing maintenance dialysis for chronic kidney disease who do not have hyperparathyroidism will not reduce their risk of certain cardiovascular events with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe